Search

Couldn't make it to the American Society of Clinical Oncology's annual meeting this year? Read this summary of some main takeaways.

… Monday, June 4, 2018 Summary Memorial Sloan Kettering researchers unveiled the results of more than 300 studies at this year’s American Society of Clinical Oncology annual meeting. These are a few of the highlights. Every year, cancer doctors and scientists from around the world converge on the sprawling

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.

… Thursday, January 17, 2019 Summary Researchers have found that the higher the tumor mutational burden of a person’s cancer, the more likely they are to respond to checkpoint inhibitor drugs. Very early on in the development of the immunotherapy drugs called checkpoint inhibitors doctors realized that

Since 2019, the Robbins Family Foundation has sponsored awards to honor MSK nurses’ extraordinary achievements and contributions to MSK’s mission and core values.

… Wednesday, May 10, 2023 Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that eight distinguished MSK nurses and one nursing team were honored with the 2023 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses

New MSK research reveals how dormant metastatic cancer cells protect themselves from the immune system by changing their shape.

… Thursday, January 15, 2026 Cancer cells that have broken away from a primary tumor can lurk in the body for years in a dormant state, evading immune defenders and biding their time until conditions are ripe for establishing a new tumor elsewhere in the body, a process known as metastasis. The vast majority

Discoveries made at Memorial Sloan Kettering receive recognition at the 2014 Annual Meeting of the American Association for Cancer Research.

… Thursday, April 10, 2014 Summary Discoveries made at Memorial Sloan Kettering receive recognition at the 2014 Annual Meeting of the American Association for Cancer Research. Two Memorial Sloan Kettering studies about targeted cancer therapies received recognition in the press program for one of the nation

Tobias M. Hohl, MD, PhD, Chief of the Infectious Diseases Service in the Department of Medicine, was elected a 2022 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest scientific society and publisher of the Science journals. This title is one of the most distinguished honors within the scientific community and is designed to recognize leaders for their notable contributions to science.

… Friday, February 3, 2023 Tobias M. Hohl, MD, PhD , Chief of the Infectious Diseases Service in the Department of Medicine, was elected a 2022 Fellow of the American Association for the Advancement of Science  (AAAS), the world’s largest scientific society and publisher of the  Science journals. This

Read a letter from Memorial Sloan Kettering's leadership team about our commitment to our community in response to acts of racism and discrimination.

… Tuesday, June 2, 2020 We are deeply saddened by the senseless and devastating acts of racism and discrimination occurring across the country. They have no place in our communities or workplaces. It rests in our hands to do what is right, to work together to fight injustice and to be part of the solution

… Tuesday, July 1, 2014 Memorial Sloan Kettering pharmacologist Gavril Pasternak has been named a 2014 Harrington Scholar-Innovator for his work in developing a class of analgesics more potent than morphine but free from the negative side effects and potential for abuse associated with traditional opioids

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].

… Monday, April 10, 2017 Bottom Line :  Researchers from  Memorial Sloan Kettering Cancer Center  (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma

Social worker Barbara Golby gives advice for restoring confidence, setting expectations, and disclosing disease history to cancer patients and survivors looking to jump into the dating scene.

… Thursday, February 11, 2016 Summary Having cancer or a history of the disease can make the search for a relationship seem intimidating. Social worker Barbara Golby gives advice for restoring confidence, setting expectations, and disclosing disease history and shares  resources for cancer patients and